Aprea Therapeutics (APRE) FDA catalyst dates

FreeBioList tracks 1 upcoming catalyst for Aprea Therapeutics (APRE, listed on Nasdaq). It concerns APR-1051 (Advanced solid tumours (WEE1 inhibitor)).

First on the list: the Phase 1 readout for APR-1051 (Advanced solid tumours (WEE1 inhibitor)), guided by the company to Q4 2026.

The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.

Background reading: Clinical trial phases explained: Phase 1 to Phase 4.

Company ▾	Drug ▾	Effect / indication	Next catalyst ▾	Phase / type ▾	Status ▾	Source	Options
Aprea Therapeutics APRE · Nasdaq	APR-1051	Advanced solid tumours (WEE1 inhibitor)	Q4 2026 company guidance	Phase 1 readout	Verified	8-K exhibit 99.1 ↗	No
Notes — Filing states Aprea "expects to report the next clinical data update from ACESOT-1051 at a medical meeting in the fourth quarter of 2026." Source: 8-K exhibit 99.1, filed 12 Aug 2026 · verified 12 Sep 2026

Companies working on related conditions

Aktis Oncology (AKTS)Urothelial and Nectin-4 expressing solid tumours (radiopharmaceutical); Metastatic castration-resistant prostate cancer (B7-H3 radiopharmaceutical)
Arvinas (ARVN)KRAS G12D-mutant solid tumours (degrader); Relapsed/refractory non-Hodgkin lymphoma (BCL6 degrader); Parkinson’s disease (LRRK2 degrader) — biomarker data; Kenn
Compass Therapeutics (CMPX)Biliary tract cancer (DLL4 x VEGF-A bispecific); TNBC, NSCLC and Hodgkin lymphoma post-checkpoint (PD-1 x PD-L1); Solid tumours (PD-1 x VEGF-A bispecific)
Eikon Therapeutics (EIKN)Non-squamous NSCLC (TLR7/8 agonist); Melanoma — first interim analysis; Advanced solid tumours (PARP1-selective); Advanced solid tumours (WRN helicase inhibitor
Erasca (ERAS)KRAS-mutant solid tumours (pan-KRAS inhibitor); RAS-mutant solid tumours (pan-RAS inhibitor); RAS-mutant colorectal cancer
MacroGenics (MGNX)Advanced solid tumours (B7-H3 ADC); Advanced solid tumours (ADAM9 ADC); Clear cell gynaecologic cancer (PD-1 x CTLA-4)

Also due in Q4 2026

Allogene Therapeutics (ALLO)Phase 1 readout for ALLO-329, Q4 2026
MBX Biosciences (MBX)Phase 1 readout for MBX 4291, Q4 2026
Kyverna Therapeutics (KYTX)Phase 1 readout for Miv-cel (mivotacel), Q4 2026
Neumora Therapeutics (NMRA)Phase 1 readout for NMRA-511, Q4 2026
Xencor (XNCR)Phase 1 readout for XmAb819, Oct 2026
Enanta Pharmaceuticals (ENTA)Phase 1 readout for EDP-978, Q4 2026